Literature DB >> 1651860

Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections.

P Balmes1, G Clerc, B Dupont, C Labram, R Pariente, R Poirier.   

Abstract

Forty-eight patients with acute bronchitis and four with pneumonia were randomly assigned to receive five doses (500 mg on day 1, plus 250 mg/day on days 2-5) of azithromycin; 54 patients with acute bronchitis and four with pneumonia were assigned 30 doses (625 mg every eight hours for ten days) of amoxicillin/clavulanic acid (CA). The two regimens were equally effective, with clinical improvement or cure in 92% and 87% of patients respectively, bacteriological cure in 89% and 86%, with 91% and 89% of pathogens eliminated. Minor side effects occurred in 6% and 12% of patients in the two groups, respectively. No major abnormalities in laboratory safety parameters were seen in either group.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651860     DOI: 10.1007/bf01968024

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  4 in total

1.  Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.

Authors:  J Retsema; A Girard; W Schelkly; M Manousos; M Anderson; G Bright; R Borovoy; L Brennan; R Mason
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

2.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

3.  Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-AZA-9a-homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides.

Authors:  G M Bright; A A Nagel; J Bordner; K A Desai; J N Dibrino; J Nowakowska; L Vincent; R M Watrous; F C Sciavolino; A R English
Journal:  J Antibiot (Tokyo)       Date:  1988-08       Impact factor: 2.649

4.  Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution.

Authors:  A E Girard; D Girard; A R English; T D Gootz; C R Cimochowski; J A Faiella; S L Haskell; J A Retsema
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

  4 in total
  6 in total

1.  Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia.

Authors:  G Kinasewitz; R G Wood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 2.  Azithromycin for acute lower respiratory tract infections.

Authors:  Malinee Laopaiboon; Ratana Panpanich; Kyaw Swa Mya
Journal:  Cochrane Database Syst Rev       Date:  2015-03-08

Review 3.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

4.  Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis.

Authors:  J C Mertens; P W van Barneveld; H R Asin; E Ligtvoet; M R Visser; T Branger; A I Hoepelman
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

5.  Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections.

Authors:  F Bariffi; V Clini; F Ginesu; P Mangiarotti; L Romoli; G Gialdroni-Grassi
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

Review 6.  Antibiotics for community-acquired pneumonia in adult outpatients.

Authors:  Smita Pakhale; Sunita Mulpuru; Theo J M Verheij; Michael M Kochen; Gernot G U Rohde; Lise M Bjerre
Journal:  Cochrane Database Syst Rev       Date:  2014-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.